FDA partners with European agency for coronavirus vaccine development

FDA said it is partnering with the European Medicines Agency (EMA) on regulatory strategies to facilitate the development of COVID-19 vaccines.

During a March 18 meeting, regulators discussed necessary preclinical data and the need to evaluate theoretical risk for vaccine-induced disease enhancement, while acknowledging the urgency of proceeding to human clinical trials with SARS-CoV-2 candidate vaccines